Smoking cessation in patients with COPD: S3-guideline issued by the German respiratory society;Tabakentwöhnung bei COPD*: S3-Leitlinie der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V.

Pneumologie

Volumn 68, Issue 4, 2014, Pages 237-258

  Andreas, S ^a   Batra, A ^b   Behr, J ^c   Chenot, J F ^d   Gillissen, A ^e   Hering, T ^f   Herth, F J F ^g   Kreuter, M ^g   Meierjurgen R ^h   Muhlig S ⁱ   Nowak, D ^c   Pfeifer, M ^j   Raupach, T ^a   Schultz, K ^k   Sitter, H ^l   Walther, J W ^m   Worth, H ⁿ  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^e KLINIKUM KASSEL   (Germany)

^f Facharztpraxis für Pneumologie   (Germany)

^g UNIVERSITY OF HEIDELBERG   (Germany)

^h Barmer GEK   (Germany)

ⁱ CHEMNITZ UNIVERSITY OF TECHNOLOGY   (Germany)

^j UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^k Klinik Bad Reichenhall   (Germany)

^l PHILIPPS UNIVERSITY MARBURG   (Germany)

^m RUHR UNIVERSITY BOCHUM   (Germany)

ⁿ KLINIKUM FÜRTH   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; HUMAN; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SMOKING CESSATION; GERMANY; HEALTH PROMOTION; PREVENTION AND CONTROL; PROCEDURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONOLOGY; SMOKING; STANDARDS;

GERMANY; HEALTH PROMOTION; HUMANS; PRACTICE GUIDELINES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY MEDICINE; SMOKING; SMOKING CESSATION;

EID: 84897575528     PISSN: 09348387     EISSN: 14388790     Source Type: Journal    
DOI: 10.1055/s-0034-1365052     Document Type: Article

References (217)

1. Rodrigez-Roisin R. et al. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global strategy for diagnosis, management and prevention of COPD (Revised 2011). 2011; Accessed at: http://www.goldcopd.org
2. Vogelmeier C., Buhl R., Criée C. P. et al. Leitlinie der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem 2007 (COPD). Pneumologie: 2007; 61 e1 e40
3. Abholz H. H., Gillissen A., Magnussen H. et al. Bundesärztekammer (BÄK) Arbeitsgemeinschaft der Deutschen Ärztekammern Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) Nationale Versorgungs-Leitlinie COPD, Langfassung, Version 1.2. 2006
4. Phillips B., Ball C., Sackett D. Levels of evidence. Oxford Centre of Evidence-based Medicine: 2001; http://www.cebm.net/index.aspx?o=1025
5. Pabst A., Piontek D., Kraus L. et al. Substanzkonsum und substanzbezogene Störungen. Sucht: 2010; 56 327 336
6. Lampert T. Rauchen - Aktuelle Entwicklungen bei Erwachsenen. GBE kompakt 2(4) Robert Koch-Institut Berlin, Hrsg.: 2011; www.rki.de/gbe-kompakt
7. Tonnesen P., Carrozzi L., Fagerström K. O. et al. Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. Eur Respir J: 2007; 29 390 417 (Pubitemid 46231920)
8. Decramer M., Decramer M. European Respiratory Roadmap Initiative The European respiratory roadmap. Lancet: 2011; 378 1765 1767
9. O'Dell L. E. A psychobiological framework of the substrates that mediate nicotine use during adolescence. Neuropharmacology: 2009; 56 263 278
10. Markou A. Review. Neurobiology of nicotine dependence. Philos Trans R Soc Lond B Biol Sci: 2008; 363 3159 3168
11. Dani J. A., Heinemann S. Molecular and cellular aspects of nicotine abuse. Neuron: 1996; 16 905 908 (Pubitemid 26171196)
12. Corrigall W. A., Franklin K. B., Coen K. M. et al. The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology: 1992; 107 285 289
13. Govind A. P., Vezina P., Green W. N. Nicotine-induced upregulation of nicotinic receptors: underlying mechanisms and relevance to nicotine addiction. Biochem Pharmacol: 2009; 78 756 765
14. Le Foll B., Goldberg S. R. Nicotine as a typical drug of abuse in experimental animals and humans. Psychopharmacology: 2006; 184 367 381 (Pubitemid 43255853)
15. Piper M. E., Schlam T. R., Cook J. W. et al. Tobacco withdrawal components and their relations with cessation success. Psychopharmacology: 2011; 216 569 578
16. Hughes J. R. Smoking and suicide: a brief overview. Drug Alcohol Depend: 2008; 98 169 178
17. Fletcher P. J., Lê A. D., Higgins G. A. Serotonin receptors as potential targets for modulation of nicotine use and dependence. Prog Brain Res: 2008; 172 361 383
18. Brody A. L., Olmstead R. E., London E. D. et al. Smoking-induced ventral striatum dopamine release. Am J Psychiatry: 2004; 161 1211 1218 (Pubitemid 38859170)
19. Takada-Takatori Y., Kume T., Izumi Y. et al. Roles of nicotinic receptors in acetylcholinesterase inhibitor-induced neuroprotection and nicotinic receptor up-regulation. Biol Pharm Bull: 2009; 32 318 324
20. Fidler J. A., Wardle J., Brodersen N. H. et al. Vulnerability to smoking after trying a single cigarette can lie dormant for three years or more. Tobacco control: 2006; 15 205 209 (Pubitemid 43864876)
21. Fiore M. C. Treating tobacco use and dependence. Clinical practice guideline 2008 update. Rockville, MD, USA US Department of Health and Human Services. Public Health Service
22. WHO ICD10CM classification of diseases. 2013; http://www.icd10data.com/ ICD10CM/Codes/F01-F99/F10-F19/F17-
23. Nelson C. B., Wittchen H. U. Smoking and nicotine dependence. Results from a sample of 14- to 24-year-olds in Germany. European addiction research: 1998; 4 42 49 (Pubitemid 28163793)
24. Center for Disease Control and Prevention (CDC) Cigarette smoking among adults - United States, 1995. MMWR Morb Mortal Wkly Rep: 1997; 46 1217 1220
25. Prochaska J. O., DiClemente C. C. Stages and processes of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol: 1983; 51 390 395
26. West R., Sohal T. Catastrophic pathways to smoking cessation: findings from national survey. BMJ: 2006; 332 458 460 (Pubitemid 43342044)
27. Andreas S., Rittmeyer A. Epidemiologie und Bedeutung tabakassoziierter Lungenkrankheiten. Der Pneumologe: 2012; 9 177 184
28. Andreas S., Batra A., Behr J. et al. Tabakentwçhnung bei COPD. S3 Leitlinie herausgegeben von der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin. Pneumologie: 2008; 62 255 272
29. Pauwels R. A., Rabe K. F. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet: 2004; 364 613 620 (Pubitemid 39094180)
30. Murray C. J., Lopez A. D. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet: 1997; 349 1498 1504 (Pubitemid 27216360)
31. Shahab L., Jarvis M. J., Britton J. et al. Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample. Thorax: 2006; 61 1043 1047 (Pubitemid 44852021)
32. de Marco R., Accordini S., Cerveri I. et al. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax: 2004; 59 120 125 (Pubitemid 38223482)
33. Chapman K. R., Mannino D. M., Soriano J. B. et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J: 2006; 27 188 207 (Pubitemid 43092683)
34. Nowak D., Berger K., Lippert B. et al. Epidemiology and health economics of COPD across Europe: a critical analysis. Treatments in respiratory medicine: 2005; 4 381 395 (Pubitemid 41803325)
35. Buist A. S., McBurnie M. A., Vollmer W. M. et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet: 2007; 370 741 750 (Pubitemid 47321907)
36. Burney P., Suissa S., Soriano J. B. et al. The pharmacoepidemiology of COPD: recent advances and methodological discussion. Eur Respir J: 2003; 43 1s 44s
37. Lundbäck B., Lindberg A., Lindström M. et al. Not 15 but 50% of smokers develop COPD? - Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med: 2003; 97 115 122 (Pubitemid 36284990)
38. Miravitlles M., Soriano J. B., García-Río F. et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. Thorax: 2009; 64 863 868
39. European Commission; Office for Official Publications of the European Communities Tobacco or Health in the European Union - past, present and future. The ASPECT Consortium: 2004
40. Wedzicha J. A., Donaldson G. C. Exacerbations of chronic obstructive pulmonary disease. Respiratory care: 2003; 48 1204 1213
41. Doll R., Peto R., Boreham J. et al. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ: 2004; 328 1519
42. Lokke A., Lange P., Scharling H. et al. Developing COPD: a 25 year follow up study of the general population. Thorax: 2006; 61 935 939 (Pubitemid 44787161)
43. Parrott S., Godfrey C. Economics of smoking cessation. BMJ: 2004; 328 947 949
44. Prescott E., Bjerg A. M., Andersen P. K. et al. Gender difference in smoking effects on lung function and risk of hospitalization for COPD: results from a Danish longitudinal population study. Eur Respir J: 1997; 10 822 827 (Pubitemid 27180193)
45. Xu X., Li B., Wang L. L. Gender difference in smoking effects on adult pulmonary function. The Eur Respir J: 1994; 7 477 483 (Pubitemid 24099008)
46. Chapman K. R. Chronic obstructive pulmonary disease: are women more susceptible than men? Clinics in chest medicine: 2004; 25 331 341 (Pubitemid 38507652)
47. Hunninghake G. M., Cho M. H., Tesfaigzi Y. et al. MMP12, lung function, and COPD in high-risk populations. N Engl J Med: 2009; 361 2599 2608
48. Rennard S. I., Vestbo J. COPD: the dangerous underestimate of 15%. Lancet: 2006; 367 1216 1219 (Pubitemid 44316602)
49. Falk G. A., Briscoe W. A. Alpha-1-antitrypsin deficiency in chronic obstructive pulmonary disease. Annals of internal medicine: 1970; 72 427 429
50. Rabe K. F., Beghé B., Luppi F. et al. Update in chronic obstructive pulmonary disease 2006. Am J Respir Crit Care Med: 2007; 175 1222 1232 (Pubitemid 46905748)
51. Anthonisen N. R., Skeans M. A., Wise R. A. et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Annals of internal medicine: 2005; 142 233 239 (Pubitemid 40216240)
52. Sin D. D., Wu L., Man S. F. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest: 2005; 127 1952 1959
53. Andreas S., Anker Stefan S. D., Scanlon P. D. et al. Neurohumoral activation as a link to systemic manifestations of chronic lung disease. Chest: 2005; 128 3618 3624 (Pubitemid 41698701)
54. Yanbaeva D. G., Dentener M. A., Creutzberg E. C. et al. Systemic effects of smoking. Chest: 2007; 131 1557 1566 (Pubitemid 46762366)
55. Cerveri I., Accordini S., Corsico A. et al. Chronic cough and phlegm in young adults. Eur Respir J: 2003; 22 413 417 (Pubitemid 37098920)
56. Vestbo J., Prescott E., Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med: 1996; 153 1530 1535 (Pubitemid 26141336)
57. Kerstjens H. A., Rijcken B., Schouten J. P. et al. Decline of FEV1 by age and smoking status: facts, figures, and fallacies. Thorax: 1997; 52 820 827 (Pubitemid 27412566)
58. Fletcher C., Peto R. The natural history of chronic airflow obstruction. British medical journal: 1977; 1 1645 1648 (Pubitemid 8124466)
59. Gold D. R., Wang X., Wypij D. et al. Effects of cigarette smoking on lung function in adolescent boys and girls. N Engl J Med: 1996; 335 931 937 (Pubitemid 26314446)
60. Sherrill D. L., Lebowitz M. D., Knudson R. J. et al. Smoking and symptom effects on the curves of lung function growth and decline. Am Rev Respir Dis: 1991; 144 17 22
61. 1: new insight into gender differences. Eur Respir J: 1994; 7 1056 1061 (Pubitemid 24187324)
62. Anthonisen N. R. Lung Health Study. Am Rev Respir Dis: 1989; 140 871 872 (Pubitemid 19259479)
63. Anthonisen N. R., Connett J. E., Murray R. P. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med: 2002; 166 675 679 (Pubitemid 34971849)
64. Anthonisen N. R., Lindgren P. G., Tashkin D. P. et al. Bronchodilator response in the lung health study over 11 yrs. Eur Respir J: 2005; 26 45 51 (Pubitemid 40945930)
65. Scanlon P. D., Connett J. E., Waller L. A. et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med: 2000; 161 381 390 (Pubitemid 30129442)
66. Kohansal R., Martinez-Camblor P., Agustí A. et al. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med: 2009; 180 3 10
67. Pauwels R. A., Buist A. S., Calverley P. M. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med: 2001; 163 1256 1276 (Pubitemid 32378468)
68. Magnussen H., Goeckenjan G., Köhler D. et al. Guidelines to long-term oxygen therapy. Pneumologie: 2001; 55 454 464 (Pubitemid 33027793)
69. Lacasse Y., LaForge J., Maltais F. Got a match? Home oxygen therapy in current smokers. Thorax: 2006; 61 374 375 (Pubitemid 43723317)
70. Yin P., Jiang C. Q., Cheng K. K. et al. Passive smoking exposure and risk of COPD among adults in China: the Guangzhou Biobank Cohort Study. Lancet: 2007; 370 751 757 (Pubitemid 47320799)
71. Jaakkola M. S., Jaakkola J. J. Impact of smoke-free workplace legislation on exposures and health: possibilities for prevention. Eur Respir J: 2006; 28 397 408 (Pubitemid 44914242)
72. Ebbert J. O., Croghan I. T., Schroeder D. R. et al. Association between respiratory tract diseases and secondhand smoke exposure among never smoking flight attendants: a cross-sectional survey. Environ Health: 2007; 6 28
73. Heidrich J., Wellmann J., Heuschmann P. U. et al. Mortality and morbidity from coronary heart disease attributable to passive smoking. European heart journal: 2007; 28 2498 2502 (Pubitemid 47614272)
74. European Respiratory Society Lifting the smoke screen - 10 reasons for a smoke free Europe. Brussels: 2006; 28 ff
75. Raupach T., Radon K., Nowak D. et al. Passive smoking - health consequences and effects of exposure prevention. Pneumologie: 2008; 62 44 50 (Pubitemid 351195235)
76. Eisner M. D., Klein J., Hammond S. K. et al. Directly measured second hand smoke exposure and asthma health outcomes. Thorax: 2005; 60 814 821 (Pubitemid 41475206)
77. Lam T. H., Ho L. M., Hedley A. J. et al. Secondhand smoke and respiratory ill health in current smokers. Tobacco control: 2005; 14 307 314 (Pubitemid 41396478)
78. Eisner M. D., Balmes J., Katz P. P. et al. Lifetime environmental tobacco smoke exposure and the risk of chronic obstructive pulmonary disease. Environ Health: 2005; 4 7
79. Tashkin D. P., Celli B., Senn S. et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med: 2008; 359 1543 1554
80. Calverley P. M., Anderson J. A., Celli B. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med: 2007; 356 775 789 (Pubitemid 46294610)
81. Fabbri L. M., Calverley P. M., Izquierdo-Alonso J. L. et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet: 2009; 374 695 703
82. Jiménez-Ruiz C. A., Masa F., Miravitlles M. et al. Smoking characteristics: differences in attitudes and dependence between healthy smokers and smokers with COPD. Chest: 2001; 119 1365 1370 (Pubitemid 32686016)
83. Jiménez-Ruiz C., Miravitlles M., Sobradillo V. et al. Can cumulative tobacco consumption, FTND score, and carbon monoxide concentration in expired air be predictors of chronic obstructive pulmonary disease? Nicotine Tob Res: 2004; 6 649 653 (Pubitemid 39248151)
84. von Hertzen L., Reunanen A., Impivaara O. et al. Airway obstruction in relation to symptoms in chronic respiratory disease - a nationally representative population study. Respir Med: 2000; 94 356 363 (Pubitemid 30323571)
85. Vozoris N. T., Stanbrook M. B. Smoking prevalence, behaviours, and cessation among individuals with COPD or asthma. Respir Med: 2011; 105 477 484
86. Medici T. C., Unger S., Rüegger M. Smoking pattern of smokers with and without tobacco-smoke-related lung diseases. Am Rev Respir Dis: 1985; 131 385 388 (Pubitemid 15133598)
87. Killen J. D., Fortmann S. P., Kraemer H. C. et al. Who will relapse? Symptoms of nicotine dependence predict long-term relapse after smoking cessation. J Consult Clin Psychol: 1992; 60 797 801
88. Clark K. D., Wardrobe-Wong N., Elliott J. J. et al. Cigarette smoke inhalation and lung damage in smoking volunteers. Eur Respir J: 1998; 12 395 399 (Pubitemid 28389535)
89. van Dijk W. D., Heijdra Y., Scheepers P. T. et al. Interaction in COPD experiment (ICE): a hazardous combination of cigarette smoking and bronchodilation in chronic obstructive pulmonary disease. Medical hypotheses: 2010; 74 277 280
90. Wagena E. J., van der Meer R. M., Ostelo R. J. et al. The efficacy of smoking cessation strategies in people with chronic obstructive pulmonary disease: results from a systematic review. Respir Med: 2004; 98 805 815 (Pubitemid 39069327)
91. Yohannes A. M., Roomi J., Baldwin R. C. et al. Depression in elderly outpatients with disabling chronic obstructive pulmonary disease. Age and ageing: 1998; 27 155 160 (Pubitemid 28226954)
92. Dudley D. L., Glaser E. M., Jorgenson B. N. et al. Psychosocial concomitants to rehabilitation in chronic obstructive pulmonary disease. 3. Dealing with psychiatric disease (as distinguished from psychosocial or psychophysiologic problems). Chest: 1980; 77 677 684 (Pubitemid 10101574)
93. Isoaho R., Puolijoki H., Huhti E. et al. Chronic obstructive pulmonary disease and self-maintaining functions in the elderly - a population-based study. Scand J Prim Health Care: 1995; 13 122 127
94. O'Neill E. S. Illness representations and coping of women with chronic obstructive pulmonary disease: a pilot study. Heart & lung: 2002; 31 295 302 (Pubitemid 34774980)
95. Di Marco F., Verga M., Reggente M. et al. Anxiety and depression in COPD patients: The roles of gender and disease severity. Respir Med: 2006; 100 1767 1774 (Pubitemid 44283757)
96. Webb R. T., Kontopantelis E., Doran T. et al. Suicide risk in primary care patients with major physical diseases: a case-control study. Arch Gen Psychiatry: 2012; 69 256 264
97. Ng T. P., Niti M., Tan W. C. et al. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med: 2007; 167 60 67 (Pubitemid 46072408)
98. Vogl M., Wenig C. M., Leidl R. et al. Smoking and health-related quality of life in English general population: implications for economic evaluations. BMC public health: 2012; 12 203
99. Khaled S. M., Bulloch A. G., Williams J. V. et al. Persistent heavy smoking as risk factor for major depression (MD) incidence - evidence from a longitudinal Canadian cohort of the National Population Health Survey. Journal of psychiatric research: 2012; 46 436 443
100. Hughes J., Stead L., Lancaster T. Antidepressants for smoking cessation. Cochrane database of systematic reviews: 2004; 4 CD000031
101. Breslau N., Johnson E. O., Hiripi E. et al. Nicotine dependence in the United States: prevalence, trends, and smoking persistence. Archives of general psychiatry: 2001; 58 810 816 (Pubitemid 32979297)
102. Glassman A. H., Covey L. S., Stetner F. et al. Smoking cessation and the course of major depression: a follow-up study. Lancet: 2001; 357 1929 1932 (Pubitemid 32568334)
103. Dierker L. C., Avenevoli S., Stolar M. et al. Smoking and depression: an examination of mechanisms of comorbidity. The American journal of psychiatry: 2002; 159 947 953 (Pubitemid 34586939)
104. Covey L. S., Glassman A. H., Stetner F. Cigarette smoking and major depression. Journal of addictive diseases: 1998; 17 35 46 (Pubitemid 28156156)
105. Fortes C., Mastroeni S., Alessandra S. et al. The combination of depressive symptoms and smoking shorten life expectancy among the aged. Int Psychogeriatr: 2011; 1 7
106. Chaiton M. O., Cohen J. E., O'Loughlin J. et al. A systematic review of longitudinal studies on the association between depression and smoking in adolescents. BMC public health: 2009; 9 356
107. Goodwin R. D., Lavoie K. L., Lemeshow A. R. et al. Depression, Anxiety, and COPD: The Unexamined Role of Nicotine Dependence. Nicotine & tobacco research: 2011; 14 176 183
108. Wilhelm K., Arnold K., Niven H. et al. Grey lungs and blue moods: smoking cessation in the context of lifetime depression history. The Australian and New Zealand journal of psychiatry: 2004; 38 896 905 (Pubitemid 40028893)
109. Batra A., Lindinger P., Schütz C. Tabakbedingte Störungen Leitlinie Tabakentwöhnung. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. 2004
110. Heatherton T. F., Kozlowski L. T., Frecker R. C. et al. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. British journal of addiction: 1991; 86 1119 1127
111. Fagerström K. Determinants of tobacco use and renaming the FTND to the Fagerstrom Test for Cigarette Dependence. Nicotine Tob Res: 2012; 14 75 78
112. Anda R. F., Williamson D. F., Escobedo L. G. et al. Depression and the dynamics of smoking. A national perspective. JAMA: 1990; 264 1541 1545 (Pubitemid 20303383)
113. Killen J. D., Fortmann S. P., Kraemer H. C. et al. Interactive effects of depression symptoms, nicotine dependence, and weight change on late smoking relapse. J Consult Clin Psychol: 1996; 64 1060 1067 (Pubitemid 26349586)
114. Löwe B. PHQ-D - Gesundheitsfragebogen für Patienten. In: Schumacher J., Strauss B. eds. Klinische Interviews und Ratingskalen Göttingen. Hogrefe: 2004
115. Bakker I. M., Terluin B., van Marwijk H. W. et al. Test-retest reliability of the PRIME-MD: limitations in diagnosing mental disorders in primary care. European journal of public health: 2009; 19 303 307
116. Gräfe K., Zipfel S., Herzog W. et al. Screening psychischer Störungen mit dem Gesundheitsfragebogen für Patienten (PHQ-D) Diagnostica: 2004; 50 171 181 (Pubitemid 39436517)
117. Gilbody S., Richards D., Barkham M. Diagnosing depression in primary care using self-completed instruments: UK validation of PHQ-9 and CORE-OM. Br J Gen Pract: 2007; 57 650 652 (Pubitemid 47232634)
118. Spitzer R. L., Kroenke K., Williams J. B. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA: 1999; 282 1737 1744 (Pubitemid 29533604)
119. Riemann K., Gerber U. Standardisierung von Fragestellungen zum Rauchen: ein Beitrag zur Qualitätssicherung in der Präventionsforschung. 4 ed. Köln BZgA. Bundeszentrale für gesundheitliche Aufklärung: 2000
120. Deutsche Krebshilfe & Deutsches Krebsforschungszentrum 190; Quelle Rauchtertagebuch: Broschüre Endlich Aufatmen 2010
121. West R., Hajek P., Stead L. et al. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction: 2005; 100 299 303 (Pubitemid 40363436)
122. Hilberink S. R., Jacobs J. E., Schlösser M. et al. Characteristics of patients with COPD in three motivational stages related to smoking cessation. Patient Educ Couns: 2006; 61 449 457 (Pubitemid 43786421)
123. West R., McNeill A., Raw M. Smoking cessation guidelines for health professionals: an update. Health Education Authority. Thorax: 2000; 55 987 999
124. Humerfelt S., Eide G. E., Kvåle G. et al. Effectiveness of postal smoking cessation advice: a randomized controlled trial in young men with reduced FEV1 and asbestos exposure. Eur Respir J: 1998; 11 284 290 (Pubitemid 28108337)
125. Bize R., Burnand B., Mueller Y. et al. Biomedical risk assessment as an aid for smoking cessation. Cochrane database of systematic reviews: 2005; 4 CD004705
126. A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. JAMA: 2000; 283 3244 3254
127. Soria R., Legido A., Escolano C. et al. A randomised controlled trial of motivational interviewing for smoking cessation. Br J Gen Pract: 2006; 56 768 774 (Pubitemid 44540906)
128. Miller W. R. Motivational interviewing: research, practice, and puzzles. Addictive behaviors: 1996; 21 835 842 (Pubitemid 26330619)
129. Lai D. T., Cahill K., Qin Y. et al. Motivational interviewing for smoking cessation. Cochrane Database Syst Rev: 2010; 1 CD006936
130. Chronic obstructive pulmonary disease, National institute for clinical excellence. www.nice.org.uk/CG012NICEguideline
131. Kotz D., Wesseling G., Aveyard P. et al. Smoking cessation and development of respiratory health in smokers screened with normal spirometry. Respir Med: 2011; 105 243 249
132. Kotz D., Wesseling G., Huibers M. J. et al. Efficacy of confronting smokers with airflow limitation for smoking cessation. Eur Respir J: 2009; 33 754 762
133. Parkes G., Greenhalgh T., Griffin M. et al. Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. BMJ: 2008; 336 598 600 (Pubitemid 351439517)
134. Sundblad B. M., Larsson K., Nathell L. Lung function testing influences the attitude toward smoking cessation. Nicotine & tobacco research: 2010; 12 37 42
135. van der Aalst C. M., van den Bergh K. A., Willemsen M. C. et al. Lung cancer screening and smoking abstinence: 2 year follow-up data from the Dutch-Belgian randomised controlled lung cancer screening trial. Thorax: 2010; 65 600 605
136. van der Aalst C. M., van Klaveren R. J., van den Bergh K. AM et al. The impact of a lung cancer computed tomography screening result on smoking abstinence. Eur Respir J: 2011; 37 1466 1473
137. O'Hara P., Grill J., Rigdon M. A. et al. Design and results of the initial intervention program for the Lung Health Study. The Lung Health Study Research Group. Preventive medicine: 1993; 22 304 315 (Pubitemid 23183076)
138. Willemse B. W., Postma D. S., Timens W. et al. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Respir J: 2004; 23 464 476 (Pubitemid 38344387)
139. Anthonisen N. R., Connett J. E., Kiley J. P. et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA: 1994; 272 1497 505
140. Godtfredsen N. S., Vestbo J., Osler M. et al. Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study. Thorax: 2002; 57 967 972 (Pubitemid 35316276)
141. Polednak A. P. Trends in mortality from COPD in selected U.S. States differing in tobacco control efforts. COPD: 2010; 7 63 69
142. Kanner R. E., Anthonisen N. R., Connett J. E. et al. Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med: 2001; 164 358 364 (Pubitemid 32778199)
143. Au D. H., Bryson C. L., Chien J. W. et al. The effects of smoking cessation on the risk of chronic obstructive pulmonary disease exacerbations. Journal of general internal medicine: 2009; 24 457 463
144. Etter J. F. Short-term change in self-reported COPD symptoms after smoking cessation in an internet sample. Eur Respir J: 2010; 35 1249 1255
145. Willemse B. W., ten Hacken N. H., Rutgers B. et al. Smoking cessation improves both direct and indirect airway hyperresponsiveness in COPD. Eur Respir J: 2004; 24 391 396 (Pubitemid 39232261)
146. Williamson D. F., Madans J., Anda R. F. et al. Smoking cessation and severity of weight gain in a national cohort. N Engl J Med: 1991; 324 739 745
147. Flegal K. M., Troiano R. P., Pamuk E. R. et al. The influence of smoking cessation on the prevalence of overweight in the United States. N Engl J Med: 1995; 333 1165 1170
148. Carroll M. E., Meisch R. A. Increased drug-reinforced behaviour due to food deprivation. In: Thompson T., Dews P. B., Je B. eds. Advances in Behavioural Pharmacology. Orlando Academic Press Inc: 1984
149. Pisinger C., Jorgensen T. Weight concerns and smoking in a general population: the Inter99 study. Preventive medicine: 2007; 44 283 289 (Pubitemid 46550679)
150. Nordstrom B. L., Kinnunen T., Utman C. H. et al. Long-term effects of nicotine gum on weight gain after smoking cessation. Nicotine & tobacco research: 1999; 1 259 268
151. Hays J. T., Hurt R. D., Rigotti N. A. et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial. Annals of internal medicine: 2001; 135 423 433 (Pubitemid 32845867)
152. Marcus B. H., Albrecht A. E., King T. K. et al. The efficacy of exercise as an aid for smoking cessation in women: a randomized controlled trial. Arch Intern Med: 1999; 159 1229 1234 (Pubitemid 29269863)
153. Kadowaki T., Watanabe M., Okayama A. et al. Continuation of smoking cessation and following weight change after intervention in a healthy population with high smoking prevalence. Journal of occupational health: 2006; 48 402 406 (Pubitemid 44664510)
154. Hughes J. R., Gust S. W., Skoog K. et al. Symptoms of tobacco withdrawal. A replication and extension. Archives of general psychiatry: 1991; 48 52 59
155. Strassmann R., Bausch B., Spaar A. et al. Smoking cessation interventions in COPD: a network meta-analysis of randomised trials. Eur Respir J: 2009; 34 634 640
156. Simmons M. S., Connett J. E., Nides M. A. et al. Smoking reduction and the rate of decline in FEV(1): results from the Lung Health Study. Eur Respir J: 2005; 25 1011 1017 (Pubitemid 40823775)
157. Raupach T., Nowak D., Hering T. et al. Smoking and pulmonary diseases, positive effects of smoking cessation. Pneumologie: 2007; 61 11 14 (Pubitemid 46511742)
158. Wagena E. J., Zeegers M. P., van Schayck C. P. et al. Benefits and risks of pharmacological smoking cessation therapies in chronic obstructive pulmonary disease. Drug Saf: 2003; 26 381 403 (Pubitemid 36560712)
159. van der Meer R. M., Wagena E. J., Ostelo R. W. et al. Smoking cessation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews: 2003; 2 CD002999
160. Bednarek M., Gorecka D., Wielgomas J. et al. Smokers with airway obstruction are more likely to quit smoking. Thorax: 2006; 61 869 873 (Pubitemid 44570307)
161. Walters N., Coleman T. Comparison of the smoking behaviour and attitudes of smokers who attribute respiratory symptoms to smoking with those who do not. Br J Gen Pract: 2002; 52 132 134 (Pubitemid 34130174)
162. Anthonisen N. R., Connett J. E., Enright P. L. et al. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med: 2002; 166 333 339 (Pubitemid 34864422)
163. Sundblad B. M., Larsson K., Nathell L. High rate of smoking abstinence in COPD patients: Smoking cessation by hospitalization. Nicotine Tob Res: 2008; 10 883 890 (Pubitemid 351974069)
164. Tonnesen P., Mikkelsen K., Bremann L. Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest: 2006; 130 334 342 (Pubitemid 44266998)
165. Wagena E. J., Knipschild P. G., Huibers M. J. et al. Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Arch Intern Med: 2005; 165 2286 2292 (Pubitemid 41549926)
166. Norrhall M. F., Nilsfelt A., Varas E. et al. A feasible lifestyle program for early intervention in patients with chronic obstructive pulmonary disease (COPD): a pilot study in primary care. Primary care respiratory journal: 2009; 18 306 312
167. Wilson J. S., Fitzsimons D., Bradbury I. et al. Does additional support by nurses enhance the effect of a brief smoking cessation intervention in people with moderate to severe chronic obstructive pulmonary disease? A randomised controlled trial. Int J Nurs Stud: 2008; 45 508 517
168. Godtfredsen N. S., Lam T. H., Hansel T. T. et al. COPD-related morbidity and mortality after smoking cessation: status of the evidence. Eur Respir J: 2008; 32 844 853
169. Christenhusz L., Pieterse M., Seydel E. et al. Prospective determinants of smoking cessation in COPD patients within a high intensity or a brief counseling intervention. Patient Educ Couns: 2007; 66 162 166 (Pubitemid 46584783)
170. http://www.anbieter-raucherberatung.de/suche.php
171. Tashkin D., Kanner R., Bailey W. et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet: 2001; 357 1571 1575 (Pubitemid 32488814)
172. Hering T., Bölcskei P., Storz C. et al. Strukturierte Raucherberatung und Tabakentwöhnung - Tabakentwöhnung in der Praxis-Sprechstunde (das Tabakentwöhnungskonzept des Bundesverbandes der Pneumologen in Deutschland - BDP). In: Haustein K. ed. Vorträge der 5. Deutschen Nikotin Konferenz. Erfurt Deutsche Gesellschaft für Nikotinforschung: 2002
173. Moher M., Hey K., Lancaster T. Workplace interventions for smoking cessation. Cochrane database of systematic reviews: 2005; 2 CD003440
174. Paone G., Serpilli M., Girardi E. et al. The combination of a smoking cessation programme with rehabilitation increases stop-smoking rate. J Rehabil Med: 2008; 40 672 677
175. West R., Zatonski W., Cedzynska M. et al. Placebo-controlled trial of cytisine for smoking cessation. N Engl J Med: 2011; 365 1193 1200
176. Vardavas C. I., Anagnostopoulos N., Kougias M. et al. Acute pulmonary effects of using an e-cigarette: impact on respiratory flow resistance, impedance and exhaled nitric oxide. Chest: 2012; 141 1400 1406
177. Jiménez Ruiz C. A., Ramos Pinedo A., Cicero Guerrero A. et al. Characteristics of COPD Smokers and Effectiveness and Safety of Smoking Cessation Medications. Nicotine Tob Res: 2012; 14 1035 1039
178. Stead L. F., Perera R., Bullen C. et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev: 2008; 1 CD000146
179. Organization WH Regulation of Nicotine Replacement Therapies: An Expert Consensus. Copenhagen Regional Office for Europe: 2001
180. Silagy C., Lancaster T., Stead L. et al. Nicotine replacement therapy for smoking cessation. Cochrane database of systematic reviews: 2004; 3 CD000146
181. Tashkin D. P., Rennard S., Hays J. T. et al. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest: 2011; 139 591 599
182. Gonzales D., Rennard S. I., Nides M. et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA: 2006; 296 47 55
183. Nides M., Oncken C., Gonzales D. et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med: 2006; 166 1561 1568 (Pubitemid 44232363)
184. Oncken C., Gonzales D., Nides M. et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med: 2006; 166 1571 1577 (Pubitemid 44232364)
185. Tonstad S., Tonnesen P., Hajek P. et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA: 2006; 296 64 71
186. Jorenby D. E., Hays J. T., Rigotti N. A. et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA: 2006; 296 56 63
187. Cahill K., Stead L. F., Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane database of systematic reviews: 2011; 2 CD006103
188. Mills E. J., Wu P., Lockhart I. et al. Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: A systematic review and multiple treatment meta-analysis. Ann Med: 2012; 44 588 5897
189. Moore T. J., Glenmullen J., Furberg C. D. Prescription drugs associated with reports of violence towards others. PloS one: 2010; 5 e15337
190. Singh S., Loke Y. K., Spangler J. G. et al. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ: 2011; 183 1359 1366
191. Prochaska J. J., Hilton J. F. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ: 04 05 2012; 344 e2856
192. Arias H. R. Is the inhibition of nicotinic acetylcholine receptors by bupropion involved in its clinical actions? Int J Biochem Cell Biol: 2009; 41 2098 2108
193. Paterson N. E. Behavioural and pharmacological mechanisms of bupropion's anti-smoking effects: recent preclinical and clinical insights. Eur J Pharmacol: 2009; 603 1 11
194. Hughes J. R., Stead L. F., Lancaster T. Antidepressants for smoking cessation. Cochrane Database of Systematic Reviews: 2007; 1 CD000031
195. Bundeszentrale für gesundheitliche Aufklärung (BzgA) Kriterien guter Praxis in der Gesundheitsförderung bei sozial Benachteiligten. 2005
196. Morgan W. J. Maternal smoking and infant lung function. Further evidence for an in utero effect. Am J Respir Crit Care Med: 1998; 158 689 690 (Pubitemid 28449427)
197. Criée C. P., Novak D. Einsparpotential durch Prävention bei COPD. In: Schauder P., Berthold H., Eckel H. et al., eds. Zukunft sichern. Senkung der Zahl chronisch Kranker. Verwirklichung einer realistischen Utopie. Deutscher Ärzteverlag: 2006
198. Ruff L. K., Volmer T., Nowak D. et al. The economic impact of smoking in Germany. Eur Respir J: 2000; 16 385 390
199. Menn P., Heinrich J., Huber R. M. et al. Direct medical costs of COPD - an excess cost approach based on two population-based studies. Respir Med: 2012; 106 540 548
200. Koskenvuo K., Broms U., Korhonen T. et al. Smoking strongly predicts disability retirement due to COPD: the Finnish Twin Cohort Study. Eur Respir J: 2011; 37 26 31
201. Murray R. P., Connett J. E., Rand C. S. et al. Persistence of the effect of the Lung Health Study (LHS) smoking intervention over eleven years. Preventive medicine: 2002; 35 314 319 (Pubitemid 35365396)
202. Felten D., Raupach T., Sessler C. et al. Efficacy of a cognitive-behavioral program with pharmacological support to achieve smoking cessation. Dtsch Med Wochenschr: 2006; 131 197 202 (Pubitemid 43265374)
203. Tengs T. O., Adams M. E., Pliskin J. S. et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk analysis: 1995; 15 369 390
204. Lock K., Wilson K., Murphy D. et al. A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease. Expert Opin Pharmacother: 2011; 172 2613 2626
205. Lang K. Berechnung der Kosteneffektivität der Nikotinersatztherapie bei Patienten mit chronisch obstruktiver Lungenerkrankung. 2009; http://duepublico.uni-duisburg-essen.de/servlets/DerivateServlet/Derivate-23374/ Dissertation-KL.pdf
206. Hoogendoorn M., Feenstra T. L., Hoogenveen R. T. et al. Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD. Thorax: 2010; 65 711 718
207. Lewis K., Stern M. British Thoracic Society Recommendations for Hospital Smoking Cessation Services for Commissioners and Health Care Professionals. British Thoracic Society Reports: 2012; 4 ISSN 2040-2023
208. Kim D. K., Hersh C. P., Washko G. R. et al. Epidemiology, radiology, and genetics of nicotine dependence in COPD. Respir Res: 2011; 12 1 11
209. Pisinger C., Godtfredsen N. S., Jorgensen T. Smoking reduction and cessation reduce chronic cough in a general population: the Inter99 study. Clin Respir J: 2008; 2 41 46
210. Lapperre T. S., Sont J. K., van Schadewijk A. et al. Smoking cessation and bronchial epithelial remodelling in COPD: a cross-sectional study. Respir Res: 2007; 8 85
211. Pisinger C., Godtfredsen N. S. Is there a health benefit of reduced tobacco consumption? A systematic review. Nicotine Tob Res: 2007; 9 631 646 (Pubitemid 46930313)
212. Hilberink S. R., Jacobs J. E., Breteler M. H. et al. General practice counseling for patients with chronic obstructive pulmonary disease to quit smoking: impact after 1 year of two complex interventions. Patient Educ Couns: 2011; 83 120 124
213. Toljamo T., Kaukonen M., Nieminen P. et al. Early detection of COPD combined with individualized counselling for smoking cessation: a two-year prospective study. Scand J Prim Health Care: 2010; 28 41 46
214. Schook R. M., Postmus B. B., van den Berg R. M. et al. The finding of premalignant lesions is not associated with smoking cessation in chemoprevention study volunteers. J Thorac Oncol: 2010; 5 1240 1245
215. Bize R., Burnand B., Mueller Y. et al. Effectiveness of biomedical risk assessment as an aid for smoking cessation: a systematic review. Tobacco control: 2007; 16 151 156
216. Carpenter M. J., Strange C., Jones Y. et al. Does genetic testing result in behavioral health change? Changes in smoking behavior following testing for alpha-1 antitrypsin deficiency. Ann Behav Med: 2007; 33 22 28
217. Taylor K. L., Cox L. S., Zincke N. et al. Lung cancer screening as a teachable moment for smoking cessation. Lung Cancer: 2007; 56 125 134 (Pubitemid 46356640)